J&J’s Sedasys Sedation System Now “Approvable,” Though Some Questions Remain
This article was originally published in The Gray Sheet
Executive Summary
Outstanding FDA questions pertain to follow-up data, user training and “post-market observance and those sorts of things,” CFO Dominic Caruso told investors during the firm’s first-quarter earnings call April 17.
You may also be interested in...
Piecing Together The Interoperability Puzzle: Q&A With Julian Goldman
In a recent interview with “The Gray Sheet,” the founding director of the Medical Device Interoperability Program describes an ongoing effort to establish a clearer FDA pathway for devices designed to seamlessly communicate with other products, even those made by different manufacturers.
Biomet Offers $280 Mil. For J&J’s DePuy Trauma Biz; Bid Facilitates Synthes Deal
J&J expects the divestiture to reduce regulatory barriers to its pending $21 billion Synthes acquisition.
J&J Eyes Restructured Device Biz As New CEO Gorsky Steps In
Big changes are underway at J&J. In April, Alex Gorsky will become the company’s new CEO. And the firm plans a restructuring of its device business upon completion of its $20 billion-plus Synthes acquisition in the first half of the year.
Need a specific report? 1000+ reports available
Buy Reports
Register for our free email digests: